Skip to main content
Year archive

Lupin Ltd — 2023 filings

All 413 regulatory filings released by Lupin Ltd (LUPIN) in 2023, sourced directly from the official regulator.

413 Filings
2023 Period
2023 filings (413)
Filing Released Lang
Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%.
Regulatory Filings
2023-12-27 English
Press Release
Regulatory Filings
2023-12-27 English
Trading Window
Regulatory Filings
2023-12-27 English
Intimation of Closure of Trading Window on account of declaration of financial results for the quarter ended at December 31, 2023.
Regulatory Filings
2023-12-27 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-12-27 English
Loss of Share Certificates
Regulatory Filings
2023-12-27 English
Intimation regarding loss of share certificate by shareholder.
Regulatory Filings
2023-12-26 English
Loss of Share Certificates
Regulatory Filings
2023-12-26 English
Acquisition
Capital/Financing Update
2023-12-22 English
Lupin Atlantis Holdings SA, Switzerland, wholly owned subsidiary of Lupin Limited has signed an Asset Purchase Agreement with Sanofi, a French Multinational pharmaceutical and healthcare ....
Capital/Financing Update
2023-12-22 English
Lupin Launches Softovac Liquifibre, a first-of-its-kind liquid fibre.
Regulatory Filings
2023-12-21 English
Press Release
Regulatory Filings
2023-12-21 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-12-21 English
Intimation regarding allotment of 38092 shares under ESOP.
Regulatory Filings
2023-12-21 English
Loss of Share Certificates
Regulatory Filings
2023-12-21 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-12-21 English
Lupin Receives Approval from U.S. FDA for Allopurinol Tablets.
Regulatory Filings
2023-12-15 English
Press Release (Revised)
Regulatory Filings
2023-12-15 English
Lupin Receives Tentative Approval from U.S. FDA for Sitagliptin Tablets.
Regulatory Filings
2023-12-15 English
Press Release
Regulatory Filings
2023-12-15 English
Lupin Receives Approval from U.S. FDA for Allopurinol Tablets.
Regulatory Filings
2023-12-15 English
Press Release
Regulatory Filings
2023-12-15 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2023-12-14 English
Intimation regarding grant of 258695 stock options under ESOP, to the employees of the Company and its subsidiaries.
Capital/Financing Update
2023-12-14 English
Press Release
Regulatory Filings
2023-12-14 English
Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Chennai.
Capital/Financing Update
2023-12-14 English
Intimation regarding loss of share certificates by shareholders.
Regulatory Filings
2023-12-07 English
Loss of Share Certificates
Regulatory Filings
2023-12-07 English
Loss of Share Certificates
Regulatory Filings
2023-12-06 English
Intimation of loss of share certificate by the shareholder.
Regulatory Filings
2023-12-06 English
Press Release
Regulatory Filings
2023-12-06 English
Lupin Receives Approval from U.S. FDA for Varenicline Tablets.
Regulatory Filings
2023-12-06 English
Intimation of loss of share certificate by the shareholder.
Regulatory Filings
2023-12-05 English
Loss of Share Certificates
Regulatory Filings
2023-12-05 English
Press Release
Regulatory Filings
2023-12-01 English
Lupin Launches Turquoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the United States.
Capital/Financing Update
2023-12-01 English
Intimation of loss of share certificate by the share holder.
Regulatory Filings
2023-11-29 English
Loss of Share Certificates
Regulatory Filings
2023-11-29 English
Intimation regarding allotment of 21390 shares under ESOP.
Regulatory Filings
2023-11-24 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-11-24 English
Loss of Share Certificates
Regulatory Filings
2023-11-24 English
Intimation regarding loss of share certificate.
Regulatory Filings
2023-11-24 English
Press Release
Regulatory Filings
2023-11-23 English
Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets.
Regulatory Filings
2023-11-23 English
Press Release
Regulatory Filings
2023-11-23 English
Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07%.
Regulatory Filings
2023-11-23 English
Loss of Share Certificates
Regulatory Filings
2023-11-23 English
Intimation regarding loss of share certificate by the shareholders.
Regulatory Filings
2023-11-23 English
Lupin Launches World''s First Fixed-dose Triple Combination Drug, Vilfuro-G for COPD Management in India.
Regulatory Filings
2023-11-23 English
Press Release
Regulatory Filings
2023-11-23 English
Loss of Share Certificates
Regulatory Filings
2023-11-22 English
Intimation regarding issuance of duplicate share certificate in lieu of lost share certificate.
Regulatory Filings
2023-11-22 English
Lupin Receives Approval from U.S. FDA for Pitavastatin Tablets.
Regulatory Filings
2023-11-21 English
Press Release
Regulatory Filings
2023-11-21 English
Lupin Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets.
Regulatory Filings
2023-11-21 English
Press Release
Regulatory Filings
2023-11-21 English
Lupin Receives Approval from U.S. FDA for Ganirelix Acetate Injection.
Regulatory Filings
2023-11-17 English
Press Release
Regulatory Filings
2023-11-17 English
Transcript of the Q2 FY2024 Earnings Conference Call.
Call Transcript
2023-11-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-11-17 English
Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar.
Capital/Financing Update
2023-11-10 English
Press Release
Capital/Financing Update
2023-11-10 English
Audio recording of the Earnings Call - Q2 FY24.
Call Transcript
2023-11-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-11-09 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-11-09 English
Allotment of 26421 shares under ESOP
Regulatory Filings
2023-11-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
2023-11-08 English
Investor Presentation Q2 FY24.
Investor Presentation
2023-11-08 English
Press Release
Earnings Release Q2 2024
2023-11-08 English
Lupin Q2 FY2024 Results.
Interim / Quarterly Report Q2 2024
2023-11-08 English
Unaudited Financial Results for the quarter and half-year ended September 30, 2023.
Regulatory Filings
2023-11-08 English
Financial Result Updates
Regulatory Filings
2023-11-08 English
Lupin Launches Rocuronium Bromide Injection in the United States.
Regulatory Filings
2023-11-08 English
Press Release
Regulatory Filings
2023-11-08 English
Press Release
Regulatory Filings
2023-11-07 English
Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin and Metformin Hydrochloride Extended-Release Tablets.
Regulatory Filings
2023-11-07 English
Loss of Share Certificates
Regulatory Filings
2023-11-06 English
Intimation regarding loss of share certificate by shareholder.
Regulatory Filings
2023-11-06 English
Press Release
Capital/Financing Update
2023-11-03 English
Lupin and Zydus Sign Licensing Agreement for Co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India.
Capital/Financing Update
2023-11-03 English
Press Release
Capital/Financing Update
2023-11-02 English
Lupin Launches Diazepam Rectal Gel in the United States.
Capital/Financing Update
2023-11-02 English
Loss of Share Certificates
Regulatory Filings
2023-11-02 English
Intimation regarding loss of share certificate by shareholder.
Regulatory Filings
2023-11-02 English
Press Release
Regulatory Filings
2023-11-02 English
Lupin Receives Tentative Approval from U.S. FDA for Selexipag for Injection.
Regulatory Filings
2023-11-02 English
Press Release
Regulatory Filings
2023-10-31 English
Lupin Receives EIR from U.S. FDA for its Mandideep Unit-2 Manufacturing Facility.
Regulatory Filings
2023-10-31 English
Earnings Call for Q2 FY24 is scheduled to be held on Thursday, November 9, 2023, at 19.00 hrs (IST).
Regulatory Filings
2023-10-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-10-31 English
Intimation regarding loss of share certificates by shareholders.
Regulatory Filings
2023-10-31 English
Loss of Share Certificates
Regulatory Filings
2023-10-31 English
Intimation regarding loss of share certificate by shareholders.
Regulatory Filings
2023-10-27 English
Loss of Share Certificates
Regulatory Filings
2023-10-27 English
Intimation regarding loss of share certificates by shareholder.
Regulatory Filings
2023-10-26 English
Loss of Share Certificates
Regulatory Filings
2023-10-26 English
Board Meeting — LUPIN LIMITED has informed the Exchange about Board Meeting to be held on 08-Nov-2023 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period…
Regulatory Filings
2023-10-25 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings
2023-10-25 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 ,inter alia, to consider and approve the unaudited financial results of the ....
Regulatory Filings
2023-10-25 English
Lupin Receives Approval from U.S. FDA for Fluconazole Tablets, USP.
Regulatory Filings
2023-10-23 English
Press Release
Regulatory Filings
2023-10-23 English
Intimation regarding issuance of duplicate share certificates.
Regulatory Filings
2023-10-23 English
Loss of Share Certificates
Regulatory Filings
2023-10-23 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-10-18 English
Loss of Share Certificates
Regulatory Filings
2023-10-18 English
Intimation of allotment of 18663 shares under ESOP.
Regulatory Filings
2023-10-18 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-10-18 English
The Company has entered into a Business Transfer Agreement with Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company.
Capital/Financing Update
2023-10-16 English
Updates
Regulatory Filings
2023-10-16 English
Lupin receives Tentative Approval from U. S. FDA for Apalutamide Tablets.
Capital/Financing Update
2023-10-13 English
Press Release
Regulatory Filings
2023-10-13 English
Intimation of loss of share certificates by shareholders.
Regulatory Filings
2023-10-13 English
Loss of Share Certificates
Regulatory Filings
2023-10-13 English
Lupin receives tentative approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution.
Regulatory Filings
2023-10-12 English
Press Release
Regulatory Filings
2023-10-12 English
Certificate pursuant to Reg 74(5) of SEBI (Depository and Participant) Regulations, 2018.
Regulatory Filings
2023-10-09 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2023-10-09 English
Intimation of Loss of share Certificates by Shareholder.
Regulatory Filings
2023-10-06 English
Loss of Share Certificates
Regulatory Filings
2023-10-06 English
Lupin Receives Tentative Approval from U.S. FDA for Tolvaptan Tablets.
Regulatory Filings
2023-10-05 English
Press Release
Regulatory Filings
2023-10-05 English
Lupin Launches Humrahi, Unique Patient Support Program for Diabetes Management.
Regulatory Filings
2023-10-03 English
Press Release
Regulatory Filings
2023-10-03 English
Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 Manufacturing Facility.
Regulatory Filings
2023-09-29 English
Press Release
Regulatory Filings
2023-09-29 English
Loss of Share Certificates
Regulatory Filings
2023-09-28 English
Trading Window
Regulatory Filings
2023-09-28 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-09-28 English
Intimation of Trading Window Closure Period.
Regulatory Filings
2023-09-28 English
Press Release
Regulatory Filings
2023-09-28 English
Lupin''s Joint Airways Initiative surpasses 10,000 patients.
Regulatory Filings
2023-09-28 English
Press Release
Capital/Financing Update
2023-09-22 English
Lupin Acquires Five Brands from Menarini.
Capital/Financing Update
2023-09-22 English
Acquisition
Capital/Financing Update
2023-09-22 English
Lupin Acquires Five Brands from Menarini.
Capital/Financing Update
2023-09-22 English
Intimation of loss of share certificate by the shareholder.
Regulatory Filings
2023-09-18 English
Loss of Share Certificates
Regulatory Filings
2023-09-18 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-09-14 English
Disclosure pursuant to allotment of 12050 shares under ESOP.
Regulatory Filings
2023-09-14 English
Intimation of loss of share certificate by the shareholder.
Regulatory Filings
2023-09-14 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-09-14 English
Loss of Share Certificates
Regulatory Filings
2023-09-14 English
Company plans to enter into a business transfer agreement with Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company, to carve out two Active Pharmaceutical Ingredients ....
Capital/Financing Update
2023-09-11 English
Updates
Capital/Financing Update
2023-09-11 English
Intimation of loss of share certificate by Shareholders.
Regulatory Filings
2023-09-11 English
Loss of Share Certificates
Regulatory Filings
2023-09-11 English
Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients.
Regulatory Filings
2023-09-06 English
Press Release
Capital/Financing Update
2023-09-06 English
Acquisition
Capital/Financing Update
2023-09-01 English
Completion of acquisition of entire share capital of French Pharmaceutical Company Medisol, consequent upon receipt of approval from the French Ministry of Economy and Finance.
Regulatory Filings
2023-09-01 English
Lupin launches Propranolol Long-Acting Capsules to improve Heart Heath in Canda.
Regulatory Filings
2023-08-29 English
Press Release
Regulatory Filings
2023-08-29 English
Lupin receives approval from U.S. FDA for Pirfenidone Capsules.
Regulatory Filings
2023-08-29 English
Press Release
Regulatory Filings
2023-08-29 English
Lupin Receives Approval from U.S. FDA for Pirfenidone Tablets.
Regulatory Filings
2023-08-25 English
Press Release
Regulatory Filings
2023-08-25 English
Lupin Acquires Brands ONDERO and ONDERO MET to expand Diabetes Portfolio in India.
Regulatory Filings
2023-08-18 English
Acquisition
Regulatory Filings
2023-08-18 English
Intimation of Loss of share certificate by the shareholder.
Regulatory Filings
2023-08-17 English
Loss of Share Certificates
Regulatory Filings
2023-08-17 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-08-17 English
Intimation of allotment of 113777 shares under ESOP.
Regulatory Filings
2023-08-17 English
Press Release
Regulatory Filings
2023-08-16 English
Lupin Launches Tiotropium Dry Powder for Inhaler for the Treatment of COPD in the United States.
Regulatory Filings
2023-08-16 English
Lupin Launches Jeet, a Patient Support Program to Raise Awareness of Cardiovascular Disease Among Patients.
Regulatory Filings
2023-08-16 English
Press Release
Regulatory Filings
2023-08-16 English
Lupin Receives Approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP.
Regulatory Filings
2023-08-16 English
Press Release
Regulatory Filings
2023-08-16 English
Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%.
Regulatory Filings
2023-08-16 English
Press Release
Regulatory Filings
2023-08-16 English
Lupin receives Approval from U. S. FDA for Doxycycline Hyclate Delayed-Release Tablets USP.
Regulatory Filings
2023-08-14 English
Press Release
Regulatory Filings
2023-08-14 English
Lupin''s Mandideep Unit-2 Facility completes U.S. FDA Inspection with No observations.
Regulatory Filings
2023-08-12 English
Transcript of the Q1 FY2024 Earnings Conference Call held on Friday, August 4, 2023.
Call Transcript
2023-08-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-08-11 English
Key Managerial Personnel authorised for the purpose of determining materiality of an event or information for making disclosures to the stock exchanges.
Regulatory Filings
2023-08-10 English
Updates
Regulatory Filings
2023-08-10 English
Lupin Receives Approval from U.S. FDA for Fluocinolone Acetonide Body Oil.
Regulatory Filings
2023-08-08 English
Lupin Digital Health Launches first-of-its-kind Digital Heart Failure Clinic in India.
Regulatory Filings
2023-08-07 English
Press Release
Regulatory Filings
2023-08-07 English
Audio recording of the Earnings Call - Q1 FY24.
Call Transcript
2023-08-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-08-04 English
Shareholders meeting
Regulatory Filings
2023-08-04 English
Scrutinizer''s Report of the Forty-First Annual General Meeting of the Company held on August 3, 2023.
Regulatory Filings
2023-08-04 English
Disclosure pursuant to grant of 10769 stock options under ESOP.
Regulatory Filings
2023-08-04 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-08-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
2023-08-04 English
Investor Presentation Q1 FY24
Investor Presentation
2023-08-04 English
Press Release
Investor Presentation
2023-08-04 English
Financial Result Updates
Regulatory Filings
2023-08-03 English
Press Release
Interim / Quarterly Report Q1 2024
2023-08-03 English
Lupin Q1 FY2024 Results.
Interim / Quarterly Report Q1 2024
2023-08-03 English
Unaudited Financial Results for the quarter ended June 30, 2023.
Regulatory Filings
2023-08-03 English
Outcome of Board Meeting
Regulatory Filings
2023-08-03 English
Shareholders meeting
AGM Information
2023-08-03 English
Proceedings at the 41st Annual General Meeting held on Thursday, August 3, 2023.
AGM Information
2023-08-03 English
Lupin Receives Approval from U. S. FDA for Fluocinolone Acetonide Topical Oil.
Regulatory Filings
2023-08-02 English
Press Release
Regulatory Filings
2023-08-02 English
Intimation of loss of share certificate by the shareholder.
Regulatory Filings
2023-08-01 English
Loss of Share Certificates
Regulatory Filings
2023-08-01 English
Press Release
Regulatory Filings
2023-08-01 English
Lupin Receives Approval from U.S. FDA for Turqoz (Norgestrel and Ethinyl Estradiol Tablets USP).
Regulatory Filings
2023-08-01 English
Press Release
Regulatory Filings
2023-07-28 English
Lupin Foundation strengthens Lives Program with its first mobile medical van; Flag-off by Health Minister, Government of Rajasthan.
Regulatory Filings
2023-07-28 English
Lupin announces Resolution of U.S. FDA warning letter for its Goa and Pithampur facilities.
Regulatory Filings
2023-07-27 English
Press Release
Regulatory Filings
2023-07-27 English
Incorporation of Lupin Manufacturing Solutions Limited, wholly owned subsidiary of the Company, for undertaking contract development and manufacturing activities.
Regulatory Filings
2023-07-26 English
Updates
Regulatory Filings
2023-07-26 English
Lupin Receives Approval from TGA Australia for Tiotropium Dry Powder for Inhaler for Treatment of COPD.
Regulatory Filings
2023-07-26 English
Press Release
Regulatory Filings
2023-07-26 English
Earnings Call Q1 FY24.
Regulatory Filings
2023-07-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-07-24 English
Press Release
Regulatory Filings
2023-07-24 English
Lupin Digital Health and The American College of Cardiology Announce First-Of-Its-Kind Collaboration to Revolutionize In-home Cardiovascular Care in India with Digital Therapeutics.
Regulatory Filings
2023-07-24 English
Board Meeting — LUPIN LIMITED has informed the Exchange about Board Meeting to be held on 03-Aug-2023 to consider and approve the Quarterly Unaudited Financial results of the Company for the period e…
Regulatory Filings
2023-07-22 English
Press Release
Regulatory Filings
2023-07-21 English
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets.
Regulatory Filings
2023-07-21 English
Lupin Launches Luforbec 100/6 for Adult Asthma and COPD Treatment in Germany.
Regulatory Filings
2023-07-21 English
Press Release
Regulatory Filings
2023-07-21 English
Updates
Regulatory Filings
2023-07-21 English
Incorporation of Lupin Atharv Ability Limited, wholly owned subsidiary of Lupin Limited, for neuro-rehabilitation business.
Regulatory Filings
2023-07-21 English
Board Meeting — Financial Results/Other business matters
Board/Management Information
2023-07-21 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2023 ,inter alia, to consider and approve the unaudited financial results of the ....
Board/Management Information
2023-07-21 English
Acquisition
Regulatory Filings
2023-07-20 English
NCLT, Mumbai, has approved Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries ....
Regulatory Filings
2023-07-20 English
Updates
Regulatory Filings
2023-07-18 English
Submission of the Revised Integrated Report of the Company for the year ended March 31, 2023, along with the Notice of the Forty-First Annual General Meeting.
Regulatory Filings
2023-07-18 English
Lupin Receives Approval from U.S. FDA for Chlorpromazine Hydrochloride Tablets USP.
Regulatory Filings
2023-07-14 English
Press Release
Regulatory Filings
2023-07-14 English
Business Responsibility and Sustainability Report of the Company for the year ended March 31, 2023.
Environmental & Social Information
2023-07-12 English
Updates
Environmental & Social Information
2023-07-12 English
Submission of the Integrated Report of the Company for the year ended March 31, 2023 along with the Notice of the Forty-First Annual General Meeting.
Regulatory Filings
2023-07-12 English
U.S. FDA Inspection of the Company''s Nagpur Oral Solid Dosage Facility.
Regulatory Filings
2023-07-12 English
Updates
Regulatory Filings
2023-07-12 English
Press Release
Regulatory Filings
2023-07-11 English
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility.
Regulatory Filings
2023-07-11 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-07-10 English
Loss of Share Certificates
Regulatory Filings
2023-07-10 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification
2023-07-09 English
Disclosure in respect of allotment of 16139 shares under ESOP.
Regulatory Filings
2023-07-06 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-07-06 English
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2023.
Regulatory Filings
2023-07-05 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2023-07-05 English
Press Release
Regulatory Filings
2023-07-04 English
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Tablets for Oral Suspension.
Regulatory Filings
2023-07-04 English
Forty-First Annual General Meeting to be held on Thursday, August 3, 2023.
AGM Information
2023-07-04 English
The Company has fixed Friday, July 14, 2023, as the ''Record Date'' for the purpose of ascertaining the shareholders who will be entitled to payment of Dividend.
AGM Information
2023-07-04 English
Record Date
AGM Information
2023-07-04 English
Lupin Receives Approval from U.S. FDA for Cyanocobalamin Nasal Spray.
Regulatory Filings
2023-07-03 English
Press Release
Regulatory Filings
2023-07-03 English
Lupin announces achievement of Key Milestone for its Phase 1 Clinical Stage MALT1 inhibitor Program.
Regulatory Filings
2023-06-29 English
Press Release
Capital/Financing Update
2023-06-29 English
Loss of Share Certificates
Regulatory Filings
2023-06-29 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-06-29 English
Lupin Launches Rufinamide Oral Suspension in the United States.
Regulatory Filings
2023-06-23 English
Press Release
Regulatory Filings
2023-06-23 English
Disclosure in respect of allotment of 17466 shares under ESOP.
Regulatory Filings
2023-06-22 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-06-22 English
Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler.
Regulatory Filings
2023-06-21 English
Press Release (Revised)
Regulatory Filings
2023-06-21 English
Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler.
Regulatory Filings
2023-06-21 English
Press Release
Regulatory Filings
2023-06-21 English
Lupin Signs MoU with Government of Maharashtra to Combat Rising Prevalence of Cardiovascular Diseases and COPD.
Regulatory Filings
2023-06-20 English
Press Release
Regulatory Filings
2023-06-20 English
Trading Window
Regulatory Filings
2023-06-19 English
Intimation of Closure of Trading Window starting from July 1, 2023.
Regulatory Filings
2023-06-19 English
Loss of Share Certificates
Regulatory Filings
2023-06-19 English
Intimation of loss of share certificate by the shareholder.
Regulatory Filings
2023-06-19 English
Press Release
Regulatory Filings
2023-06-19 English
Lupin Receives EIR from U.S. FDA for its API Manufacturing Facility in Vizag.
Regulatory Filings
2023-06-19 English
Lupin Launches Thiamine Hydrochloride Injection USP in the United States.
Regulatory Filings
2023-06-19 English
Press Release
Regulatory Filings
2023-06-19 English
Lupin Launches Darunavir Tablets in the United States
Regulatory Filings
2023-06-03 English
Press Release
Regulatory Filings
2023-06-03 English
Lupin Receives Approval from U.S. FDA for Diazepam Rectal Gel.
Regulatory Filings
2023-06-01 English
Press Release
Regulatory Filings
2023-06-01 English
Lupin Receives Approval from U.S. FDA for Obeticholic Acid Tablets.
Regulatory Filings
2023-05-31 English
Press Release
Regulatory Filings
2023-05-31 English
Press Release
Capital/Financing Update
2023-05-30 English
Lupin Announces the Launch of Cetuximab.
Regulatory Filings
2023-05-30 English
Press Release
Regulatory Filings
2023-05-26 English
Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD.
Regulatory Filings
2023-05-26 English
Press Release
Capital/Financing Update
2023-05-25 English
Lupin Diagnostics Launches Satellite Laboratory in Vijayawada.
Capital/Financing Update
2023-05-25 English
Disclosure in respect of allotment of 36689 shares under ESOP.
Regulatory Filings
2023-05-25 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-05-25 English
Transcript of the Q4 FY2023 Earnings Conference Call held at 16.00 hrs (IST)on Wednesday, May 10, 2023.
Call Transcript
2023-05-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-05-16 English
Audio/Video recording of the Earnings Call - Q4 FY 2023.
Call Transcript
2023-05-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-05-10 English
Investor Presentation Q4 FY23.
Regulatory Filings
2023-05-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-05-10 English
Annual Secretarial Compliance Report for the year ended March 31, 2023.
Regulatory Filings
2023-05-10 English
Annual Secretarial Compliance Report
Regulatory Filings
2023-05-10 English
Related Party Transactions
Regulatory Filings
2023-05-09 English
Press Release
Interim / Quarterly Report FY 2023
2023-05-09 English
Lupin Q4 FY2023 Results.
Interim / Quarterly Report FY 2023
2023-05-09 English
Approval of the Audited Financial Statements for the quarter and year ended March 31, 2023 and recommend final dividend @ 200% i.e. Rs. 4/- per equity share of the face value of Rs. 2/- ....
Regulatory Filings
2023-05-09 English
Dividend
Regulatory Filings
2023-05-09 English
Audited Financial Statements for the quarter and year ended March 31, 2023.
Regulatory Filings
2023-05-09 English
Financial Result Updates
Regulatory Filings
2023-05-09 English
Acquisition of French Pharmaceutical Company Medisol.
Capital/Financing Update
2023-05-05 English
Press Release
M&A Activity
2023-05-05 English
Acquisition of French Pharmaceutical Company Medisol.
M&A Activity
2023-05-05 English
Acquisition
M&A Activity
2023-05-05 English
Disclosure pursuant to grant of 13953 stock options under ESOP.
Capital/Financing Update
2023-05-05 English
ESOP/ESOS/ESPS
Capital/Financing Update
2023-05-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-04-29 English
Earnings Call - Quarter IV, FY 2023.
Regulatory Filings
2023-04-29 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-04-26 English
Disclosure pursuant to allotment of 44528 shares under ESOP.
Regulatory Filings
2023-04-26 English
Board Meeting — LUPIN LIMITED has informed the Exchange about Board Meeting to be held on 09-May-2023 to consider financial statements for the period ended March 2023, Financial results/Dividend/Othe…
Regulatory Filings
2023-04-25 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings
2023-04-25 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2023 ,inter alia, to consider and approve the audited financial results of the ....
Regulatory Filings
2023-04-25 English
Lupin Diagnostics Launches Regional Reference Laboratory in Bengaluru, Strengthening Presence in South India.
Regulatory Filings
2023-04-12 English
Press Release
Capital/Financing Update
2023-04-12 English
Compliance ceritifcate under Reg. 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended at March 31, 2023.
Regulatory Filings
2023-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2023-04-04 English
Compliance certificate for the year ended at March 31, 2023 under Reg. 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Filings
2023-04-04 English
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations,2018 for the quarter ended at March 31, 2023.
Regulatory Filings
2023-04-04 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings
2023-04-03 English
Loss of Share Certificates
Regulatory Filings
2023-03-31 English
Intimation regardig issuance of duplicate share certificate.
Regulatory Filings
2023-03-31 English
Lupin Receives Approval from U.S. FDA for Tenofovir Alafenamide Tablets.
Regulatory Filings
2023-03-31 English
Press Release
Regulatory Filings
2023-03-31 English
U.S. FDA Inspection of the Company's Manufacturing Facility at Pithampur Unit-2.
Regulatory Filings
2023-03-30 English
Updates
Regulatory Filings
2023-03-30 English
Lupin Receives Tentative Approval from U.S. FDA for Valbenazine Capsules.
Regulatory Filings
2023-03-27 English
Press Release
Regulatory Filings
2023-03-27 English
Press Release
Regulatory Filings
2023-03-25 English
Lupin Announces Successful Completion of UK MHRA Inspection of its Pithampur Facilities.
Regulatory Filings
2023-03-25 English
Press Release
Regulatory Filings
2023-03-25 English
Lupin Announces Completion of Pharmacovigilance Inspection by the U.S. FDA with No Observations.
Regulatory Filings
2023-03-25 English
Lupin Receives Tentative Approval from U.S. FDA for Obeticholic Acid Tablets.
Regulatory Filings
2023-03-23 English
Press Release
Regulatory Filings
2023-03-23 English
Press Release
Regulatory Filings
2023-03-21 English
Lupin Receives Approval from U.S. FDA for Brexpiprazole Tablets.
Regulatory Filings
2023-03-21 English
Press Release
Regulatory Filings
2023-03-20 English
Lupin's Alliance Partner Caplin Receives U.S. FDA Approval for Rocuronium Bromide Injection.
Regulatory Filings
2023-03-20 English
Press Release
Regulatory Filings
2023-03-20 English
Lupin's Alliance Partner Caplin Receives U.S. FDA Approval for Thiamine Hydrochloride Injection USP.
Regulatory Filings
2023-03-20 English
Press Release
Regulatory Filings
2023-03-17 English
Lupin Digital Health Unveils Results of India's First Digital Therapeutics Study with ACS Patients.
Regulatory Filings
2023-03-17 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-03-17 English
Intimation in respect of allotment of 24914 shares under ESOP.
Regulatory Filings
2023-03-17 English
Lupin Bioresearch Centre Completes U.S. FDA Inspection with No Observations.
Regulatory Filings
2023-03-13 English
Press Release
Regulatory Filings
2023-03-13 English
Press Release
Regulatory Filings
2023-03-10 English
U.S. FDA Completes Inspection of Lupin's Vizag Facility with No Observations.
Regulatory Filings
2023-03-10 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-03-03 English
Intimation of allotment of 15638 shares under ESOP.
Regulatory Filings
2023-03-03 English
Press Release
Regulatory Filings
2023-03-01 English
Lupin Diagnostics Expands Presence in South India with New Regional Reference Laboratory in Hyderabad.
Regulatory Filings
2023-03-01 English
Credit rating on enhanced bank facilities.
Regulatory Filings
2023-02-23 English
Credit Rating
Regulatory Filings
2023-02-23 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-02-23 English
Disclosure in respect of Grant of 26099 stock options under Lupin Subsidiary Companies Employees Stock Option Plan 2014.
Regulatory Filings
2023-02-23 English
Lupin Launches Lurasidone Hydrochloride Tablets in the United States.
Regulatory Filings
2023-02-21 English
Press Release
Regulatory Filings
2023-02-21 English
Lupin Receives EIR from U.S. FDA for its Injectable Facility in Nagpur.
Regulatory Filings
2023-02-17 English
Press Release
Regulatory Filings
2023-02-17 English
Transcript of Q3 FY2023 Earnings Conference Call.
Call Transcript
2023-02-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-02-16 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-02-16 English
Disclosure in respect of allotment of 65284 shares under ESOP on Februrary 16, 2023.
Regulatory Filings
2023-02-16 English
Lupin Launches Atharv Ability - State-of-the-Art, Multi-Disciplinary Neuro-Rehabilitation Center in Mumbai.
Regulatory Filings
2023-02-14 English
Press Release
Regulatory Filings
2023-02-14 English
Link of audio recording of the Earnings Call - Q3 FY 2023.
Regulatory Filings
2023-02-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2023-02-11 English
Investor Presentation - Q3 FY 23.
Investor Presentation
2023-02-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
2023-02-10 English
Lupin Q3 FY2023 Results.
Interim / Quarterly Report Q3 2023
2023-02-09 English
Press Release
Earnings Release Q3 2023
2023-02-09 English
Unaudited standalone and consolidated financial results of the Company along with Limited Review Report for the quarter and nine-months ended December 31, 2022.
Regulatory Filings
2023-02-09 English
Financial Result Updates
Regulatory Filings
2023-02-09 English
Lupin Receives Approval from U.S. FDA for Glycopyrrolate Injection, USP.
Regulatory Filings
2023-02-09 English
Press Release
Regulatory Filings
2023-02-09 English
Lupin Launches Aptivate Champion Run for Kids Promoting Well-being and Good Eating Habits
Regulatory Filings
2023-02-03 English
Press Release
Regulatory Filings
2023-02-03 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-01-31 English
Disclosure pursuant to grant of 33137 stock options under Lupin Subsidiary Companies Employees Stock Option Plan 2014.
Regulatory Filings
2023-01-31 English
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets.
Regulatory Filings
2023-01-31 English
Press Release
Regulatory Filings
2023-01-31 English
Earnings Call for Quarter - III, FY 2023 scheduled to be held on Friday, February 10, 2023, at 16.00 hrs (IST).
Call Transcript
2023-01-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-01-28 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 ,inter alia, to consider and approve unaudited financial results of the ....
Regulatory Filings
2023-01-25 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings
2023-01-25 English
Press Release
Regulatory Filings
2023-01-24 English
Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care.
Regulatory Filings
2023-01-24 English
ESOP/ESOS/ESPS
Regulatory Filings
2023-01-20 English
Disclosure pursuant to allotment of 114899 shares under ESOP.
Regulatory Filings
2023-01-20 English
Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients.
Regulatory Filings
2023-01-18 English
Press Release
Regulatory Filings
2023-01-18 English
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets.
Regulatory Filings
2023-01-16 English
Press Release
Regulatory Filings
2023-01-16 English
U.S. FDA Inspection of the Company's Somerset manufacturing facility.
Regulatory Filings
2023-01-15 English
Updates
Regulatory Filings
2023-01-15 English
Investor Presentation
Investor Presentation
2023-01-11 English
J. P Morgan Healthcare Conference, US.
Investor Presentation
2023-01-11 English
Press Release
Regulatory Filings
2023-01-10 English
Lupin Receives Approval from U.S. FDA for Prasugrel Tablets, USP.
Regulatory Filings
2023-01-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2023-01-09 English
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarted ended at December 31, 2022.
Regulatory Filings
2023-01-09 English
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders.
Regulatory Filings
2023-01-09 English
Press Release
Regulatory Filings
2023-01-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2023-01-08 English
J. P. Morgan Healthcare Conference on Tuesday, January 10, 2023.
Investor Presentation
2023-01-08 English
Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets.
Regulatory Filings
2023-01-06 English
Press Release
Regulatory Filings
2023-01-06 English
Press Release
Regulatory Filings
2023-01-05 English
Lupin Launches novel fixed-dose triple drug combination DIFIZMA® DPI to Treat Inadequately Controlled Asthma.
Regulatory Filings
2023-01-05 English
Loss of Share Certificates
Regulatory Filings
2023-01-04 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2023-01-04 English